de Heus, Rianne A. A. published the artcileBlood pressure lowering with nilvadipine in patients with mild-to-moderate Alzheimer disease does not increase the prevalence of orthostatic hypotension, Recommanded Product: Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, the main research area is Alzheimer disease orthostatic hypotension nilvadipine blood pressure; Alzheimer disease; adverse drug event; antihypertensive agent; calcium channel blocker; orthostatic hypotension; randomized controlled trial.
This secondary anal. of randomized controlled trial assessed whether antihypertensive treatment increases prevalence of orthostatic hypotension in patients with Alzheimer disease. Methods and Results-Four hundred seventy-seven patients with mild-to-moderate Alzheimer disease were randomized to the calcium-channel blocker nilvadipine 8 mg/day or placebo for 78 wk. Presence of OH (blood pressure drop â?0/â?0 mm Hg after 1 min of standing) and OH-related adverse events (dizziness, syncope, falls, and fractures) was determined at 7 follow-up visits. Mean age of the study population was 72.2 ± 8.2 years and mean Mini-Mental State Examination score was 20.4 ± 3.8. Baseline blood pressure was 137.8 ± 14.0/77.0 ± 8.6 mm Hg. Grade I hypertension was present in 53.4%. After 13 wk, blood pressure had fallen by 7.8/-3.9 mm Hg for nilvadipine and by -0.4/-0.8 mm Hg for placebo . Across the 78-wk intervention period, there was no difference between groups in the proportion of patients with OH at study visit, nor in proportion of visits where a patient met criteria for OH, corrected for number of visits. OH-related adverse events were not more often reported in the intervention group compared with placebo. Results were similar for those with baseline hypertension. Conclusions-This study suggests that initiation of a low dose of antihypertensive treatment does not significantly increase the risk of OH in patients with mild-to-moderate Alzheimer disease.
Journal of the American Heart Association published new progress about Alzheimer disease. 21829-25-4 belongs to class pyridine-derivatives, name is Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C17H18N2O6, Recommanded Product: Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.